Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: Results from the prostate cancer prevention trial

William D. Figg; Cindy H. Chau; Douglas K. Price; Cathee Till; Phyllis J. Goodman; Yonggon Cho; Marileila Varella-Garcia; Juergen K.V. Reichardt; Catherine M. Tangen; Robin J. Leach; Adrie Van Bokhoven; Ian M. Thompson; M. Scott Lucia

doi:10.1016/j.urology.2014.03.015

Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: Results from the prostate cancer prevention trial

William D. Figg, Cindy H. Chau, Douglas K. Price, Cathee Till, Phyllis J. Goodman, Yonggon Cho, Marileila Varella-Garcia, Juergen K.V. Reichardt, Catherine M. Tangen, Robin J. Leach, Adrie Van Bokhoven, Ian M. Thompson, M. Scott Lucia

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Objective To investigate the association between the length of the polymorphic trinucleotide CAG microsatellite repeats in exon 1 of the AR gene and the risk of prostate cancer containing TMPRSS2:ETS fusion genes. Methods This nested case-control study came from subjects enrolled in the Prostate Cancer Prevention Trial and included 195 biopsy-proven prostate cancer cases with a known TMPRSS2:ETS status and 1344 matched controls. Results There was no association between the CAG repeat length and the risk of TMPRSS2:ETS-positive (odds ratio, 0.97; 95% confidence interval, 0.91-1.04) or TMPRSS2:ETS-negative prostate cancer (odds ratio, 1.04; 95% confidence interval, 0.97-1.11) and in patients with low- or high-grade disease. Conclusion Our findings suggested that AR CAG repeats are not associated with TMPRSS2:ETS formation in prostate cancer.

Original language	English (US)
Pages (from-to)	127-131
Number of pages	5
Journal	Urology
Volume	84
Issue number	1
DOIs	https://doi.org/10.1016/j.urology.2014.03.015
State	Published - 2014

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.urology.2014.03.015

Cite this

Figg, W. D., Chau, C. H., Price, D. K., Till, C., Goodman, P. J., Cho, Y., Varella-Garcia, M., Reichardt, J. K. V., Tangen, C. M., Leach, R. J., Van Bokhoven, A., Thompson, I. M., & Lucia, M. S. (2014). Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: Results from the prostate cancer prevention trial. Urology, 84(1), 127-131. https://doi.org/10.1016/j.urology.2014.03.015

Figg, WD, Chau, CH, Price, DK, Till, C, Goodman, PJ, Cho, Y, Varella-Garcia, M, Reichardt, JKV, Tangen, CM, Leach, RJ, Van Bokhoven, A, Thompson, IM & Lucia, MS 2014, 'Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: Results from the prostate cancer prevention trial', Urology, vol. 84, no. 1, pp. 127-131. https://doi.org/10.1016/j.urology.2014.03.015

@article{26744a81565242838566426a087cc2ba,

title = "Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: Results from the prostate cancer prevention trial",

abstract = "Objective To investigate the association between the length of the polymorphic trinucleotide CAG microsatellite repeats in exon 1 of the AR gene and the risk of prostate cancer containing TMPRSS2:ETS fusion genes. Methods This nested case-control study came from subjects enrolled in the Prostate Cancer Prevention Trial and included 195 biopsy-proven prostate cancer cases with a known TMPRSS2:ETS status and 1344 matched controls. Results There was no association between the CAG repeat length and the risk of TMPRSS2:ETS-positive (odds ratio, 0.97; 95% confidence interval, 0.91-1.04) or TMPRSS2:ETS-negative prostate cancer (odds ratio, 1.04; 95% confidence interval, 0.97-1.11) and in patients with low- or high-grade disease. Conclusion Our findings suggested that AR CAG repeats are not associated with TMPRSS2:ETS formation in prostate cancer.",

author = "Figg, {William D.} and Chau, {Cindy H.} and Price, {Douglas K.} and Cathee Till and Goodman, {Phyllis J.} and Yonggon Cho and Marileila Varella-Garcia and Reichardt, {Juergen K.V.} and Tangen, {Catherine M.} and Leach, {Robin J.} and {Van Bokhoven}, Adrie and Thompson, {Ian M.} and Lucia, {M. Scott}",

year = "2014",

doi = "10.1016/j.urology.2014.03.015",

language = "English (US)",

volume = "84",

pages = "127--131",

journal = "Urology",

issn = "0090-4295",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk

T2 - Results from the prostate cancer prevention trial

AU - Figg, William D.

AU - Chau, Cindy H.

AU - Price, Douglas K.

AU - Till, Cathee

AU - Goodman, Phyllis J.

AU - Cho, Yonggon

AU - Varella-Garcia, Marileila

AU - Reichardt, Juergen K.V.

AU - Tangen, Catherine M.

AU - Leach, Robin J.

AU - Van Bokhoven, Adrie

AU - Thompson, Ian M.

AU - Lucia, M. Scott

PY - 2014

Y1 - 2014

N2 - Objective To investigate the association between the length of the polymorphic trinucleotide CAG microsatellite repeats in exon 1 of the AR gene and the risk of prostate cancer containing TMPRSS2:ETS fusion genes. Methods This nested case-control study came from subjects enrolled in the Prostate Cancer Prevention Trial and included 195 biopsy-proven prostate cancer cases with a known TMPRSS2:ETS status and 1344 matched controls. Results There was no association between the CAG repeat length and the risk of TMPRSS2:ETS-positive (odds ratio, 0.97; 95% confidence interval, 0.91-1.04) or TMPRSS2:ETS-negative prostate cancer (odds ratio, 1.04; 95% confidence interval, 0.97-1.11) and in patients with low- or high-grade disease. Conclusion Our findings suggested that AR CAG repeats are not associated with TMPRSS2:ETS formation in prostate cancer.

AB - Objective To investigate the association between the length of the polymorphic trinucleotide CAG microsatellite repeats in exon 1 of the AR gene and the risk of prostate cancer containing TMPRSS2:ETS fusion genes. Methods This nested case-control study came from subjects enrolled in the Prostate Cancer Prevention Trial and included 195 biopsy-proven prostate cancer cases with a known TMPRSS2:ETS status and 1344 matched controls. Results There was no association between the CAG repeat length and the risk of TMPRSS2:ETS-positive (odds ratio, 0.97; 95% confidence interval, 0.91-1.04) or TMPRSS2:ETS-negative prostate cancer (odds ratio, 1.04; 95% confidence interval, 0.97-1.11) and in patients with low- or high-grade disease. Conclusion Our findings suggested that AR CAG repeats are not associated with TMPRSS2:ETS formation in prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=84903689279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903689279&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2014.03.015

DO - 10.1016/j.urology.2014.03.015

M3 - Article

C2 - 24824408

AN - SCOPUS:84903689279

SN - 0090-4295

VL - 84

SP - 127

EP - 131

JO - Urology

JF - Urology

IS - 1

ER -

Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: Results from the prostate cancer prevention trial

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this